Early immune markers of clinical, virological, and immunological outcomes in patients with COVID-19: a multi-omics study
Article
[키워드] Abuse
Accelerator
Antibody Response
association
Biomarker
BNT162b2
characterized
clinical trial
coronavirus
Course
COVID-19
COVID-19 patients
Critical
CXCL10
cytokine
dataset
develop
Disease progression
Donor
drug
early IFN signaling
Eiger BioPharmaceuticals
enrolled
Enrollment
heterogeneity
Host
identify
immune
immune marker
immune response
immune signature
immunological
immunology
independent
individual
Infection
Infectious disease
Inflammation
machine-learning
majority
marker
MCP-3
MCP1
Medicine
memory
Mild
mRNA vaccination
natural infection
outcome
Outpatient
outpatients
Patient
Pfizer-BioNTech
plasma
plasma protein
Post-infection
predict
Predictive
Predictive modeling
proteomics
provided
receiving
RIG-I
SARS-CoV-2
SARS-CoV-2-infected patients
severe symptoms
Stanford
Stanford University
subsequent
systems immunology
T cell
T cell memory
the antibody response
trajectory
transcriptomics
Vaccine
viral shedding
Virological
viruses
with COVID-19
[DOI] 10.7554/eLife.77943 PMC 바로가기
[DOI] 10.7554/eLife.77943 PMC 바로가기